Metabolic Research Institute Inc.
Welcome,         Profile    Billing    Logout  
 4 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Horowitz, Barry M
SURPASS-SWITCH, NCT05564039: A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide

Active, not recruiting
4
250
Europe, US, RoW
Tirzepatide, LY3298176, Dulaglutide, LY2189265
Eli Lilly and Company
Type 2 Diabetes
08/24
08/24
DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended
3
675
Europe, Canada, US, RoW
Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Anji Pharma
Diabetes Mellitus, Type 2
12/23
06/24
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Recruiting
3
2620
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
04/25
12/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
07/25
07/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting
2
168
Canada, US
Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg
Zucara Therapeutics Inc.
Type 1 Diabetes Mellitus With Hypoglycemia
06/25
07/25
NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Recruiting
2
240
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
03/25
06/25
HORIZON, NCT05583344: Phase 2b Study of GSK4532990 in Adults With NASH

Recruiting
2
246
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Nonalcoholic Fatty Liver Disease
09/25
12/25
SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed
N/A
343
US
Omnipod 5 Automated Glucose Control System
Insulet Corporation, Jaeb Center for Health Research
Type2 Diabetes
03/24
03/24

Download Options